



Canadian spotlight 15.1: Key additions from the first half of March 2022

In the first half of March, contributing Canadian evidence-synthesis teams have shared with us six newly completed evidence syntheses which are listed in the table below. All the syntheses provide insight focused on public-health measures (n=6).

Taxonomy section	Title	Type of product	Date of last search (and publication)	Evidence synthesis team
<ul style="list-style-type: none"> Public-health measures 	What is the effectiveness of available COVID-19 vaccines for children and adolescents, including variants of concern?	Update to a living evidence synthesis	2022-03-02 (published 2022-03-04)	Faculty of Medicine, University of Antioquia & Health Information Research Unit, McMaster University
<ul style="list-style-type: none"> Public-health measures 	What is the long-term effectiveness of available COVID-19 vaccines for adults, including for variants of concern and over time frames beyond 112 days in those with a primary series and beyond 84 days in those with a primary series and an additional dose?	Living evidence synthesis	2022-03-02 (published 2022-03-03)	Montreal Behavioural Medicine Centre, Concordia University
<ul style="list-style-type: none"> Public-health measures 	What is the effectiveness of available COVID-19 vaccines for variants of concern in adults over time frames up to 120 days?	Update to a living evidence synthesis	2022-03-02 (published 2022-03-02)	Health Information Research Unit, McMaster University
<ul style="list-style-type: none"> Public-health measures 	Association between mask mandates and population-level COVID-19 outcomes – What we know so far	Evidence synthesis	2022-02-15 (published 2022-03-04)	Public Health Ontario
<ul style="list-style-type: none"> Public-health measures 	Living profile of SARS-CoV-2 Omicron (B.1.1.529) variant of concern (For those interested in accessing the full copy of the rapid review, please	Update to a living evidence review	2022-02-16 (published 2022-02-16)	Emerging Science Group, Public Health Agency of

	contact phac.ocsoevidence-bcsdonneesprobantes.aspc@canada.ca)			Canada (PHAC)
<ul style="list-style-type: none"> Public-health measures 	<p>Evidence brief on attitudes and acceptance of COVID-19 booster doses</p> <p>(For those interested in accessing the full copy of the rapid review, please contact phac.ocsoevidence-bcsdonneesprobantes.aspc@canada.ca)</p>	Evidence brief	2022-01-31 (published 2022-01-31)	Emerging Science Group, Public Health Agency of Canada (PHAC)